Financial Outlook
Bausch Health announced an upgraded full‑year 2026 outlook, now expecting consolidated revenue between $10.975 billion and $11.175 billion and adjusted EBITDA ranging from $4.315 billion to $4.415 billion. The company also raised its adjusted cash‑flow‑from‑operations target (excluding Bausch + Lomb) to a range of $1.600 billion‑$1.675 billion.
Quarterly Performance (Q3, ended 30 September 2026)
Revenue for the quarter increased 10% year‑over‑year to $2.941 billion, up from $2.681 billion in the prior year. Adjusted earnings per share rose to $1.77 from $1.16, while net income attributable to Bausch Health climbed to $436 million from $179 million. Adjusted EBITDA attributable to Bausch Health (excluding Bausch + Lomb) grew 32% to $1.305 billion, up from $986 million. Consolidated operating income rose to $983 million from $619 million, and cash provided by operating activities more than doubled, reaching $813 million versus $405 million a year earlier.
Segment Highlights
- Salix revenue expanded 16% to $831 million, driven by a 16% increase in Xifaxan sales.
- Bausch + Lomb generated $1.375 billion in revenue, a 7% year‑over‑year rise.
- Solta Medical reported reported‑basis revenue of $165 million, an 18% increase, although organic revenue declined 4%.
Balance‑Sheet Progress and Share Repurchase
During the quarter the company reduced net debt by more than $500 million. The board authorized a $50 million share‑repurchase programme, primarily intended to offset dilution from management equity awards expected to vest in 2027.
Management Commentary
Chief Executive Officer Thomas J. Appio highlighted that, for the first time, Bausch Health excluding Bausch + Lomb generated over $1 billion in adjusted EBITDA in a single quarter. He noted the achievement of the 14th consecutive quarter of year‑over‑year revenue and adjusted EBITDA growth, underscoring confidence in sustaining momentum across the pharmaceutical and eye‑care businesses.